Ms. Lacks’s family accused Novartis of profiting from her cells, which were taken from her without her consent in 1951, when ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

Irish and American researchers have identified a potential new way to counter treatment‑resistant prostate cancer by ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers.

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

Scientists in Brazil are refining the design of CAR-engineered immune cells to make them more precise and powerful against cancer.

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell that's effective against solid tumors, which ...

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell ...

Scientists in Dublin and Tampa, Florida have published a new strategy for treating radiation-resistant cancers.

NÖK Therapeutics, Inc. (“NÖK”), a clinical-stage biotechnology company advancing novel Natural Killer (“NK”) cell immunotherapies, today announced that members of its leadership team will participate ...